REVB · Revelation Biosciences, Inc.
$1.14
+0.02 (+1.79%)
At close · Aug 7
Going-concern doubt
— flagged Aug 6, 2026
Substantial doubt about the company's ability to continue as a going concern.
“The Company does not anticipate that its current cash and cash equivalents balance will be sufficient to sustain operations within one year after the date that the Company's unaudited condensed financial statements for June 30, 2026 were issued, which raises substantial doubt about its ability to continue as a going concern.”View the 10-Q filed Aug 6, 2026
Market Cap
$4.54M
Shares
3.98M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$1.14
Open$1.03
Day$1.03–1.20
52W$0.88–11.72
Avg vol 30d42K
Short int20K · 0.5% float · 1.0d
Short vol7%
DataNov 2020–Aug 2026
Filing10-Q · Aug 6
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 6, 2026
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Neutral
Momentum
Weak
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 14.9 · calm
Equity put/call 0.57
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−45%
below
Price vs 50-day avg
+9%
above
RSI (14)
58
neutral
MACD trend
Positive
52-week position
2%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+14%
trailing
6-month return
−22%
trailing
YTD return
−64%
this year
Relative strength
−36%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $1 › 200d $2 — 200d above 50d
Institutional flow
Flat
2 of 12 funds reported for Jun 30 · net 0 sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
0.51% of float · ▲ +44.9% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
12 holders — mid 3-yr range
Squeeze score
63
elevated · 0–100
Fundamentals
EPS growth
+98%
Y/Y
Free cash flow
$-8.3M
Valuation
P/E 0
in line
Balance sheet
$10.7M
net cash
Quant / Vol
risk profile
Volatility
77%
annualized · 1-yr
Max drawdown
−92%
past year
ATR
7.0%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−45%
Bearish
Price vs 50-day avg
+9%
Bullish
RSI (14)
58
Neutral
MACD trend
Positive
Bullish
52-week position
2%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bearish · 1 of 6
Trend (MA cross)
No cross
50d $1 › 200d $2 — 200d above 50d
Institutional flow
Flat
2 of 12 funds reported for Jun 30 · net 0 sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
0.51% of float · ▲ +44.9% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
12 holders — mid 3-yr range
Price context
position in its 52-week range
52-wk low $1
Now $1 · 2%
52-wk high $12
vs 200-day avg -45%
vs 50-day avg +9%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
REVB
this stock
Revelation Biosciences, Inc.
|
$4.54M | -64.4% | — | 0.0 | 0.5% |
|
ONC
BeOne Medicines Ltd.
|
$487.49B | +14.6% | +22179.2% | 749.6 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$122.68B | +9.4% | +46.2% | 28.2 | 2.0% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$79.49B | +1.9% | +20.8% | 19.1 | 3.4% |
|
ARGX
Argenx SE
|
$54.76B | +2.9% | — | — | 2.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| REVB | +20.0% | +14.0% | -22.5% | +20.0% | -64.4% |
| SPY | +3.5% | +2.4% | +13.4% | +3.5% | +13.4% |
| vs SPY | +16.5% | +11.6% | -35.9% | +16.5% | -77.8% |